Tom Fitton, the President of Judicial Watch released more information on an investigation by group, that is shocking and disturbing. The evidence he has brought to light should be investigated and held up to public scrutiny.
According to a press release from Judicial Watch:
Judicial Watch has uncovered more documents detailing the evil activities of your federal government – the trafficking of the remains of unborn human beings killed by abortion.
We received another 198 pages of records and communications from the U.S. Food and Drug Administration (FDA) involving “humanized mice” research with human fetal heads, organs and tissue, including communications and contracts with human fetal tissue provider Advanced Bioscience Resources (ABR).
We received the records through a March 2019 FOIA lawsuit against the U.S. Department of Health and Human Services, of which the FDA is a part (Judicial Watch v. U.S. Department Health and Human Services (No. 1:19-cv-00876)).
Our lawsuit asks for all contracts and related documentation on disbursement of funds, procedural documents and communications between FDA and ABR for the provision of human fetal tissue to be used in humanized mice research. After we successfully opposed the FDA’s redaction of certain information from its records, a federal court ordered HHS to release additional information about its purchases of organs harvested from aborted human fetuses – including “line item prices,” or the price per organ the government paid to ABR. The court also found “there is reason to question” whether the transactions violate federal law barring the sale of fetal organs. Documents previously uncovered in this lawsuit show that the federal government demanded the purchased fetal organs be “fresh and never frozen.”)
The records include an FDA generated contract with ABR, based on a “requisition” it issued on July 27, 2012, for $12,000 worth of “tissue procurement for humanized mice,” which indicates the requisition was for a “non-competitive award.” Although the initial award was for $12,000, the total estimated amount of funds allocated for the requisition was $60,000. Under “Justification for Other than Full and Open Competition,” the FDA writes:
A January 1, 2013, “Fees for Services Schedule” provided by ABR to the FDA includes:
[Dilation and Evacuation abortion]
(13-24 weeks) per specimen $275
The fees for services schedule also includes “Special Processing/Preservation” of the fetal parts, such as “Tissue ‘Cleaning,’” “Snap freezing,” and “Passive freezing (Dry ice).”
In a September 9, 2014, “Order for Supplies or Services,” the FDA writes regarding a $9,900 order:
As the result of an August 21, 2015, “Amendment of Solicitation/Modification of Contract,” ABR bumped up the price of baby livers and thymuses from $325 each to $340 each.
A “Tissue Acquisition Quote” sent by ABR to Howard on July 5, 2017, provided a quote of $5,440 each to provide 16 sets of second trimester (16-24 weeks) livers and 16 sets of second trimester (16-24 weeks) thymuses at $340 per “sample.” The request for the quote notes that “tissue known to be positive for HIV, HepA, HepB, HepC or chromosomal abnormalities are not acceptable.”
On June 28, 2017, a redacted FDA contract specialist sends Larton at ABR a request for a quote (RFQ) of pricing for human fetal tissue, aged “16-24 weeks,” including a “Statement of Needs”:
A May 2018, report from a company named “LABS,” which was employed by ABR to test fetal parts and their mothers for hepatitis and HIV, notes in its “methodology description” that they are approved by the FDA “for living and cadaveric donor screening.”
The records include a recitation of requirements by the FDA for “Payment by Electronic Funds Transfer,” in which ABR must adhere to regulations relating to “Convict Labor” and “Child Labor-Cooperation with Authorities and Remedies.”
On September 24, 2018, the Trump FDA terminated its contract with ABR for human tissue purchases and began an audit of its acquisitions of baby body parts. The records include the FDA’s letter terminating the contract:
Here’s some background.
In February 2020, we first uncovered through this lawsuit hundreds of pages of records from the National Institutes of Health (NIH) showing that the agency paid thousands of dollars to a California-based firm to purchase organs from aborted human fetuses to create “humanized mice” for HIV research.
In May 2021, this lawsuit uncovered FDA records showing the agency spent tens of thousands of taxpayer dollars to buy human fetal tissue from ABR. The tissue was used in creating “humanized mice” to test “biologic drug products.” The records indicated the FDA wanted tissue purchases “Fresh; shipped on wet ice.”
On August 3, 2021, we announced that The Center for Medical Progress (CMP) and Judicial Watch, through a separate lawsuit, received 252 pages of new documents from the U.S. Department of Health and Human Services that reveal nearly $3 million in federal funds were spent on the University of Pittsburgh’s quest to become a “Tissue Hub” for human fetal tissue ranging from 6 to 42 weeks’ gestation. The Pitt scientists note that, “All fetal tissue is collected through a collaborative process including Family Planning, Obstetrics and Pathology.” Pitt anticipated “being able to harvest and distribute quality tissue and cells … [and] do not anticipate any major problems related to the acquisition and distribution of the tissues.” Pitt’s target goal “is to have available a minimum of 5 cases (tissues and if possible other biologicals) per week of gestational age for ages 6-42 weeks.”
Chopping up aborted human beings for their organs and tissue is a moral and legal outrage. This issue should be front and center in any debate about America’s barbaric abortion industry.
Kari is an ex-Community Organizer who writes about Cultural Marxism, grassroots activism, music, IndyCar racing and political campaigns. @Saorsa1776